Raloxifene: a review of its use in the prevention of invasive breast cancer.
Raloxifene (Evista) is a second-generation selective estrogen receptor modulator (SERM) that functions as an estrogen antagonist on breast and uterine tissues, and an estrogen agonist on bone. It is available in many countries worldwide for the treatment and prevention of osteoporosis in postmenopausal women, and has also been approved in the US for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women at increased risk of invasive breast cancer.Raloxifene reduces the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer and in postmenopausal women with osteoporosis. In addition, it is a well established agent for the prevention and treatment of osteoporosis. There was no significant difference between raloxifene and tamoxifen in the reduction in the risk of invasive breast cancer achieved in postmenopausal women at high risk of such cancer. Raloxifene was associated with an increased, albeit rare, risk of venous thromboembolism across several placebo-controlled trials and an increased risk of fatal stroke in one placebo-controlled trial in postmenopausal woman at increased risk for major coronary events. However, raloxifene was associated with a lower risk of venous thromboembolic events and cataracts than tamoxifen in a head-to-head trial. The choice of chemoprevention agent must consider a risk-benefit assessment for each individual patient. In this context, raloxifene is a valuable option for the prevention of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of invasive breast cancer.
Moen
Marit D
MD
Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz
Keating
Gillian M
GM
D001943:Breast Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000523:psychology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000150:complications; D011788:Quality of Life; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride
J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61
15572757
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
2593165
J Natl Cancer Inst. 2001 Mar 7;93(5):334-5
11238688
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
9747868
JAMA. 2002 Jan 9;287(2):216-20
11779264
J Natl Cancer Inst. 2007 Sep 5;99(17):1282-3, 1289
17728206
Breast Cancer Res Treat. 2006 Jul;98(2):167-72
16538534
Clin Cancer Res. 2006 Sep 1;12(17):5242-7
16951244
Gynecol Endocrinol. 2001 Jun;15(3):225-33
11447735
Menopause. 2003 Jul-Aug;10(4):337-44
12851517
Curr Med Res Opin. 2005 Sep;21(9):1441-52
16197663
Am J Ther. 2006 Jul-Aug;13(4):337-48
16858170
J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8
10491430
JAMA. 1998 May 13;279(18):1445-51
9600478
JAMA. 2006 Jun 21;295(23):2742-51
16754728
Metabolism. 2005 Jul;54(7):939-46
15988705
Life Sci. 1983 Jun 20;32(25):2869-75
6406781
Arch Intern Med. 2000 Dec 11-25;160(22):3444-50
11112238
JAMA. 2002 Feb 20;287(7):847-57
11851576
Am J Obstet Gynecol. 2003 Feb;188(2):389-94
12592245
Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):23-9
10428318
JAMA. 1999 Aug 18;282(7):637-45
10517716
JAMA. 2006 Jun 21;295(23):2727-41
16754727
J Natl Cancer Inst. 2008 Jun 18;100(12):831-3
18544739
Breast Cancer Res Treat. 2008 Apr;108(3):435-53
17554628
BJOG. 2008 May;115(6):773-9
18355366
N Engl J Med. 2006 Jul 13;355(2):125-37
16837676
Maturitas. 2008 Jun 20;60(2):92-107
18534794
Menopause. 2002 Mar-Apr;9(2):110-6
11875329
Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):961-6
11535548
Clin Ther. 2004 Jun;26(6):830-40
15262454
Obstet Gynecol. 2000 Jan;95(1):95-103
10636510
Int Semin Surg Oncol. 2007 Jul 23;4:18
17645796
N Engl J Med. 1997 Dec 4;337(23):1641-7
9385122
J Natl Cancer Inst. 2006 Sep 6;98(17):1172-3
16954464
JAMA. 2006 Jun 21;295(23):2784-6
16754726
Breast Cancer Res Treat. 2001 Jan;65(2):125-34
11261828
J Clin Oncol. 2007 Nov 1;25(31):4967-73
17971595
Br J Pharmacol. 2007 Jan;150(1):3-4
17115068
J Clin Endocrinol Metab. 2000 Jun;85(6):2197-202
10852452
J Bone Miner Res. 2002 Feb;17(2):341-8
11811565
Br J Clin Pharmacol. 2005 Apr;59(4):479-82
15801944
Anticancer Res. 2006 Jan-Feb;26(1B):735-44
16739346
Am J Psychiatry. 2005 Apr;162(4):683-90
15800139
Drugs Aging. 1998 Apr;12(4):335-41; discussion 342
9571395
Int J Clin Pract. 2007 Dec;61(12):2051-63
17892469
Drugs. 2000 Aug;60(2):379-411
10983739
JAMA. 1999 Jun 16;281(23):2189-97
10376571
J Natl Cancer Inst. 2001 Jan 3;93(1):51-6
11136842
Cancer. 2000 May 1;88(9):2047-53
10813716
J Clin Oncol. 2001 Jun 15;19(12):3111-6
11408508
Cancer Res. 1985 Feb;45(2):584-90
3967234
Clin Pharmacokinet. 2003;42(4):361-72
12648026
Biochem Pharmacol. 2006 May 14;71(10):1459-69
16554039
Br J Cancer. 2001 Dec 14;85(12):1838-41
11747323
Arch Intern Med. 2004 Apr 26;164(8):871-9
15111373
Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1468-73
14693739
J Fam Pract. 2004 Oct;53(10):789-96
15469774
J Natl Cancer Inst. 1996 Jan 17;88(2):123-5
8537973
Arch Intern Med. 2001 Jul 9;161(13):1639-44
11434796
Expert Opin Pharmacother. 2006 Nov;7(16):2301-7
17059385
J Clin Endocrinol Metab. 1997 Oct;82(10):3425-9
9329380
Curr Med Res Opin. 2008 Mar;24(3):807-13
18254988
Pharm Res. 2001 Jul;18(7):1024-8
11496940
Expert Opin Drug Saf. 2008 May;7(3):259-70
18462184
Oncology. 1988;45(5):344-5
3412740
J Natl Cancer Inst. 2008 Jun 18;100(12):854-61
18544744
N Engl J Med. 2001 Apr 19;344(16):1207-13
11309635